Table 2.
Summary of the effects of zinc supplementation in MHD patients.
| Factor | Number of studies | Heterogeneity test | Weighted mean difference | Publication bias | |||||
|---|---|---|---|---|---|---|---|---|---|
| Q | I 2 | P value | WMD | [95% CI] | P value | Begg test | Egger test | ||
| Serum zinc (ug/dL) | 13 | 81.98 | 90.7% | <0.001 | 28.489 | [26.264, 30.713] | <0.001∗ | 0.502 | 0.355 |
| BMI (kg/m2) | 3 | 1.34 | 0% | 0.511 | 0.149 | [−0.762, 1.059] | 0.794 | 1.000 | 0.263 |
| nPNA (g/kg/d) | 4 | 11.31 | 91.20% | 0.001 | 0.135 | [−0.161, 0.431] | 0.371 | 1.000 | 0.657 |
| Dietary protein intake (g/kg/d) | 2 | 0.27 | 0% | 0.604 | 8.012 | [1.592, 14.408] | <0.001∗ | - | - |
| Albumin (g/dL) | 4 | 9.74 | 69.20% | 0.021 | 0.358 | [−0.016, 0.732] | 0.061 | 0.734 | 0.276 |
| Hemoglobin (g/dL) | 4 | 16.27 | 81.6% | 0.013 | 0.756 | [−0.011, 1.522] | 0.053 | 1.000 | 0.654 |
| HDL (mg/dL) | 4 | 24.6 | 91.90% | <0.001 | 4.048 | [−3.142, 11.238] | 0.27 | 1.000 | 0.847 |
| LDL (mg/dL) | 4 | 24.46 | 91.80% | <0.001 | 21.028 | [−15.478, 57.534] | 0.259 | 1.000 | 0.749 |
| TC (mg/dL) | 5 | 22.97 | 86.90% | <0.001 | 16.198 | [−9.975, 42.371] | 0.225 | 0.734 | 0.624 |
| TG (mg/dL) | 3 | 8.2 | 75.60% | 0.017 | 0.207 | [−34.711, 35.125] | 0.991 | 1.000 | 0.327 |
| CRP (ng/mL) | 3 | 13.85 | 85.60% | 0.001 | −8.618 | [−15.579, −1.656] | 0.015∗ | 1.000 | 0.783 |
| MDA (nmol/mL) | 3 | 16.32 | 87.70% | <0.001 | −1.275 | [−1.945, −0.605] | <0.001∗ | 0.296 | 0.287 |
| SOD (U/g Hb) | 2 | 3.42 | 70.80% | 0.064 | 357.568 | [152.158, 562.978] | 0.001∗ | - | - |
Note. -: values could not be calculated due to an insufficient number of studies; ∗P < 0.05, and WMD was considered statistically significant.